303 related articles for article (PubMed ID: 28115333)
21. Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
Chen L; Hua J; Hong SJ; Yuan CY; Jing RC; Luo XY; Xue HW; Yue Y; He XP
J Antimicrob Chemother; 2023 Mar; 78(3):710-718. PubMed ID: 36691860
[TBL] [Abstract][Full Text] [Related]
22. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
23. Resistance to empirical β-lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study.
Chumbita M; Puerta-Alcalde P; Yáñez L; Cuesta MA; Chinea A; Español Morales I; Fernández Abellán P; Gudiol C; Guerreiro M; González-Sierra P; Rojas R; Sánchez Pina JM; Sánchez Vadillo I; Varela R; Vázquez L; Lopera C; Monzó P; Garcia-Vidal C
J Antimicrob Chemother; 2022 Jun; 77(7):2017-2023. PubMed ID: 35466357
[TBL] [Abstract][Full Text] [Related]
24. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
25. Colonization With Levofloxacin-resistant Extended-spectrum β-Lactamase-producing Enterobacteriaceae and Risk of Bacteremia in Hematopoietic Stem Cell Transplant Recipients.
Satlin MJ; Chavda KD; Baker TM; Chen L; Shashkina E; Soave R; Small CB; Jacobs SE; Shore TB; van Besien K; Westblade LF; Schuetz AN; Fowler VG; Jenkins SG; Walsh TJ; Kreiswirth BN
Clin Infect Dis; 2018 Nov; 67(11):1720-1728. PubMed ID: 29701766
[TBL] [Abstract][Full Text] [Related]
26. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts.
Rodríguez-Baño J; Navarro MD; Retamar P; Picón E; Pascual Á;
Clin Infect Dis; 2012 Jan; 54(2):167-74. PubMed ID: 22057701
[TBL] [Abstract][Full Text] [Related]
27. Management of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: current evidence and future prospects.
Sheu CC; Lin SY; Chang YT; Lee CY; Chen YH; Hsueh PR
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):205-218. PubMed ID: 29402125
[TBL] [Abstract][Full Text] [Related]
28. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
29. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort.
Palacios-Baena ZR; Gutiérrez-Gutiérrez B; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina Gil-Bermejo J; Hernández A; Venditti M; Prim N; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Paño-Pardo JR; Torre-Cisneros J; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual Á; Rodríguez-Baño J;
Clin Infect Dis; 2017 Oct; 65(10):1615-1623. PubMed ID: 29020250
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: A focus on antimicrobials including cefepime.
Chopra T; Marchaim D; Johnson PC; Chalana IK; Tamam Z; Mohammed M; Alkatib S; Tansek R; Chaudhry K; Zhao JJ; Pogue JM; Kaye KS
Am J Infect Control; 2015 Jul; 43(7):719-23. PubMed ID: 25934068
[TBL] [Abstract][Full Text] [Related]
31. Incidence and risk factors for acquired colonization and infection due to extended-spectrum beta-lactamase-producing Gram-negative bacilli: a retrospective analysis in three ICUs with low multidrug resistance rate.
Massart N; Camus C; Benezit F; Moriconi M; Fillatre P; Le Tulzo Y
Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):889-895. PubMed ID: 31898797
[TBL] [Abstract][Full Text] [Related]
32. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
[TBL] [Abstract][Full Text] [Related]
33. Risk Factors for Extended-Spectrum β-lactamase-Producing Enterobacterales Bloodstream Infection Among Solid-Organ Transplant Recipients.
Anesi JA; Lautenbach E; Tamma PD; Thom KA; Blumberg EA; Alby K; Bilker WB; Werzen A; Tolomeo P; Omorogbe J; Pineles L; Han JH
Clin Infect Dis; 2021 Mar; 72(6):953-960. PubMed ID: 32149327
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of gram-negative bacteremia during febrile neutropenia among allogeneic hematopoietic stem cell transplant recipients on levofloxacin prophylaxis.
Ogura S; Kimura M; Takagi S; Mitsuki T; Yuasa M; Kageyama K; Kaji D; Nishida A; Taya Y; Ishiwata K; Yamamoto H; Asano-Mori Y; Yamamoto G; Uchida N; Wake A; Taniguchi S; Araoka H
Eur J Clin Microbiol Infect Dis; 2021 May; 40(5):941-948. PubMed ID: 33185742
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
[TBL] [Abstract][Full Text] [Related]
36. Changing trends in the aetiology, treatment and outcomes of bloodstream infection occurring in the first year after solid organ transplantation: a single-centre prospective cohort study.
Oriol I; Sabé N; Simonetti AF; Lladó L; Manonelles A; González J; Tubau F; Carratalà J
Transpl Int; 2017 Sep; 30(9):903-913. PubMed ID: 28500792
[TBL] [Abstract][Full Text] [Related]
37. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study.
Gutiérrez-Gutiérrez B; Bonomo RA; Carmeli Y; Paterson DL; Almirante B; Martínez-Martínez L; Oliver A; Calbo E; Peña C; Akova M; Pitout J; Origüen J; Pintado V; García-Vázquez E; Gasch O; Hamprecht A; Prim N; Tumbarello M; Bou G; Viale P; Tacconelli E; Almela M; Pérez F; Giamarellou H; Cisneros JM; Schwaber MJ; Venditti M; Lowman W; Bermejo J; Hsueh PR; Mora-Rillo M; Gracia-Ahulfinger I; Pascual A; Rodríguez-Baño J;
J Antimicrob Chemother; 2016 Jun; 71(6):1672-80. PubMed ID: 26907184
[TBL] [Abstract][Full Text] [Related]
38. Impact of antibiotic resistance on outcomes of neutropenic cancer patients with
Albasanz-Puig A; Gudiol C; Parody R; Tebe C; Akova M; Araos R; Bote A; Brunel AS; Calik S; Drgona L; García E; Hemmati P; Herrera F; Ibrahim KY; Isler B; Kanj S; Kern W; Maestro de la Calle G; Manzur A; Marin JI; Márquez-Gómez I; Martín-Dávila P; Mikulska M; Montejo JM; Montero M; Morales HMP; Morales I; Novo A; Oltolini C; Peghin M; Del Pozo JL; Puerta-Alcalde P; Ruiz-Camps I; Sipahi OR; Tilley R; Yáñez L; Gomes MZR; Carratalà J;
BMJ Open; 2019 May; 9(5):e025744. PubMed ID: 31129580
[TBL] [Abstract][Full Text] [Related]
39. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.
Tumbarello M; Sanguinetti M; Montuori E; Trecarichi EM; Posteraro B; Fiori B; Citton R; D'Inzeo T; Fadda G; Cauda R; Spanu T
Antimicrob Agents Chemother; 2007 Jun; 51(6):1987-94. PubMed ID: 17387156
[TBL] [Abstract][Full Text] [Related]
40. Use of β-Lactam/β-Lactamase Inhibitors for Extended-Spectrum-β-Lactamase Infections: Defining the Right Patient Population.
Tamma PD; Villegas MV
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
